Aims Little is known about the tolerability profile of Aripiprazole in the TS population. We set out to evaluate the prevalence of psychiatric and non-psychiatric adverse events (PAE and nPAE) of Aripiprazole through a retrospective chart review of adult patients seen at a specialist TS clinic. Methods We reviewed the clinical files of 29 patients (22 males; mean age 29.7±13.0) who had been started on Aripiprazole (median starting dose: 5.0 mg; median maintenance dose: 10.0 mg). Results Twenty-one patients (72.4%) developed adverse effects: 6 (20.7%) PAE (most common: anxiety); 17 (58.6%) nPAE (most common: sedation). Thirteen patients (44.8%) discontinued the Aripiprazole, 6 (20.7%) solely because of the severity of specific adverse effects (sedation, sleep problems, weight gain, nausea, lost appetite, tic worsening, hot flushes). When comparing patients with and without adverse effects, we found no differences in socio-demographic or clinical variables. However, there was a trend towards a statistically significant difference in Aripiprazole starting dose (p=0.07). Conclusions The most commonly reported adverse effects of Aripiprazole treatment in TS were sedation and sleep problems. In the majority of cases, adverse effects were not severe. In our clinical sample there were no predictors for poor tolerability. Slow titration is recommended in order to minimise the occurrence of adverse effects.

Selvini, C., Cavanna, A., Termine, C., Luoni, C., Eddy, C., Rickards, H. (2011). Tolerability profile of Aripiprazole in adult patients with Tourette syndrome. Intervento presentato a: Joint Conference of the British-Neuropsychiatry-Association AGM/ Section of Neuropsychiatry of RCPsych - FEB 09-11, 2011, Inst Child Hlth, London, ENGLAND [10.1136/jnnp-2011-300504.37].

Tolerability profile of Aripiprazole in adult patients with Tourette syndrome

Cavanna A;
2011

Abstract

Aims Little is known about the tolerability profile of Aripiprazole in the TS population. We set out to evaluate the prevalence of psychiatric and non-psychiatric adverse events (PAE and nPAE) of Aripiprazole through a retrospective chart review of adult patients seen at a specialist TS clinic. Methods We reviewed the clinical files of 29 patients (22 males; mean age 29.7±13.0) who had been started on Aripiprazole (median starting dose: 5.0 mg; median maintenance dose: 10.0 mg). Results Twenty-one patients (72.4%) developed adverse effects: 6 (20.7%) PAE (most common: anxiety); 17 (58.6%) nPAE (most common: sedation). Thirteen patients (44.8%) discontinued the Aripiprazole, 6 (20.7%) solely because of the severity of specific adverse effects (sedation, sleep problems, weight gain, nausea, lost appetite, tic worsening, hot flushes). When comparing patients with and without adverse effects, we found no differences in socio-demographic or clinical variables. However, there was a trend towards a statistically significant difference in Aripiprazole starting dose (p=0.07). Conclusions The most commonly reported adverse effects of Aripiprazole treatment in TS were sedation and sleep problems. In the majority of cases, adverse effects were not severe. In our clinical sample there were no predictors for poor tolerability. Slow titration is recommended in order to minimise the occurrence of adverse effects.
abstract + poster
Neurosciences; Neurology; Psychiatry; Surgery
English
Joint Conference of the British-Neuropsychiatry-Association AGM/ Section of Neuropsychiatry of RCPsych - FEB 09-11, 2011
2011
2011
82
8
PA.10
none
Selvini, C., Cavanna, A., Termine, C., Luoni, C., Eddy, C., Rickards, H. (2011). Tolerability profile of Aripiprazole in adult patients with Tourette syndrome. Intervento presentato a: Joint Conference of the British-Neuropsychiatry-Association AGM/ Section of Neuropsychiatry of RCPsych - FEB 09-11, 2011, Inst Child Hlth, London, ENGLAND [10.1136/jnnp-2011-300504.37].
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/413678
Citazioni
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 0
Social impact